RecruitingNot ApplicableNCT04699591
Compassionate Use of Domperidone for Refractory Gastroparesis
Sponsor
Jose Cocjin
Enrollment
20 participants
Start Date
Apr 1, 2013
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this program is to allow the use of domperidone in children from 12 to 21 years of age with symptoms related to motility disorders and Gastroesophageal reflux disease (GERD) who have failed all the standard treatments for their condition.
Eligibility
Min Age: 12 YearsMax Age: 21 Years
Inclusion Criteria11
- Male or female
- Age 12 - 21
- Symptoms or manifestations secondary to GERD (e.g., persistent esophagitis, heartburn, upper airway signs or symptoms or respiratory symptoms), gastrointestinal motility disorders such as nausea, vomiting, severe dyspepsia or severe chronic constipation that are refractory to standard therapy.
- Patients must have a comprehensive evaluation to eliminate other causes of their symptoms.
- Patient has signed informed consent for the administration of domperidone that informs the patient of potential adverse events including:
- increased prolactin levels
- extrapyramidal side effects
- breast changes
- Cardiac arrhythmias including QT prolongation
- There is a potential for increased risk of adverse events with the drugs and herbal supplements listed in the addendum (See Addendum on pages 24 and 25)
- The coordinator/investigator will have a discussion with the family about the use of any of the medications and herbal supplements listed in the addendum to make sure they understand the increased risk of their use and the need to contact the investigators prior to using any of the listed medications and herbal supplements.
Exclusion Criteria7
- History of, or current, arrhythmias including ventricular tachycardia, ventricular fibrillation and Torsade des Pointes. Patients with minor forms of ectopy (PACs) are not necessarily excluded.
- Clinically significant bradycardia, sinus node dysfunction, or heart block. Prolonged Tc (QTc\> 450 milliseconds for males, QTc\>470 milliseconds for females).
- Clinically significant electrolyte disorders.
- Gastrointestinal hemorrhage or obstruction
- Presence of a prolactinoma (prolactin-releasing pituitary tumor).
- Pregnant or breast feeding female
- Known allergy to domperidone
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGDomperidone
Domperidone taken 4 times a day, dose based on body weight
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04699591
Related Trials
Pyloric Sphincter Abnormalities in Patients With Gastroparesis Symptoms
NCT046612155 locations
Gastroparesis Registry 4
NCT058468026 locations
Study on Hydrotalcite for Relief of Acid Symptoms Due to Acid Rebound After Stopping Long-Term PPI Therapy
NCT072917002 locations
GpCRC Pediatric Gastroparesis Registry 2
NCT059813006 locations
Study of Gastric Motility in Eosinophilic Gastritis
NCT052294323 locations